 FOSTER CITY, Calif.--BUSINESS WIRE--Mirum Pharmaceuticals, Inc. Nasdaq: MIRM, a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell 75.0 million of shares of its common stock. In connection with the proposed offering, Mirum expects to grant the underwriters a 30-da 